Gastroparesis Market Analysis, Size, Share & Growth Forecast 2026–2034

Metoclopramide Reglan 12-Week FDA Duration Limit From Tardive Dyskinesia Risk in 1 in 500 Patients After 3 Months of D2 Antagonism Has Created the Treatment Duration Restriction Making Chronic Gastroparesis Management With the Only Approved Prokinetic Clinically Unsatisfactory.Generic metoclopramide's dopamine D2 receptor antagonism at the gastric antrum provides the only available short-term prokinetic therapy for gastroparesis, but the FDA's black box warning for tardive dyskinesia with long-term use restricts prescription duration and creates a treatment gap for the chronic gastroparesis population who require ongoing motility support. Evoke Pharma's nasal metoclopramide Gimoti was approved as a reformulation enabling faster absorption and potentially lower peak concentrations that reduce dopaminergic CNS side effects, but commercial uptake has been limited by the substantial patient reluctance to use nasal spray for a chronic gastrointestinal condition and by payer resistance to the premium-priced reformulation over generic oral metoclopramide. The unmet need for a safe long-term prokinetic therapy in gastroparesis is driving development programmes that target ghrelin receptor agonism, motilin receptor agonism, and serotonin 5-HT4 receptor stimulation as mechanistic alternatives that avoid the dopamine-mediated CNS effects limiting metoclopramide duration.

Relamorelin Ghrelin Receptor Agonist DIGEST-1 Phase II Gastric Emptying T1/2 Reduction From 152 to 102 Minutes Has Provided the Prokinetic Mechanism Accelerating Gastric Motor Function Without the Dopamine Antagonism Tardive Dyskinesia Risk That Limits Metoclopramide to 12 Weeks.Merck's aprepitant Emend demonstrated 45% reduction in weekly vomiting frequency in a Phase 2 gastroparesis trial, providing proof of concept that the substance P-NK1 receptor pathway contributes to the nausea and vomiting component of gastroparesis that is mechanistically independent of the gastric emptying delay that prokinetics target. The mechanistic rationale for NK1 antagonism in gastroparesis involves the abundant NK1 receptors in the enteric nervous system and nucleus tractus solitarius that mediate the central vomiting reflex triggered by delayed gastric emptying-induced antral distension. The off-label use of aprepitant in refractory gastroparesis nausea and vomiting has been documented in academic medical centre case series, and a formal Phase 3 programme is being considered based on the preliminary efficacy signal and the established safety profile from years of oncology anti-emetic use that eliminates safety uncertainty for chronic gastroparesis administration.

Medtronic Enterra Gastric Electrical Stimulation FDA Humanitarian Device Exemption Controlling Nausea and Vomiting in Refractory Gastroparesis Without Improving Gastric Emptying Has Established the Neurostimulation Palliative Option When Prokinetic Pharmacotherapy Fails.Medtronic's Enterra Therapy gastric electrical stimulation system received humanitarian device exemption approval for drug-refractory, chronic intractable nausea and vomiting secondary to diabetic or idiopathic gastroparesis, with compassionate use and registry data showing 60-70% improvement in nausea and vomiting frequency despite variable effects on gastric emptying rate. The mechanism of Enterra involves high-frequency low-energy electrical pulses to the gastric antrum that reduce vagal afferent signalling driving nausea without achieving the muscle contraction that would improve emptying, explaining the clinical dissociation between symptom improvement and gastric scintigraphy outcomes. The HDE pathway creates regulatory and commercial constraints where widespread adoption is limited by the approval's restriction to refractory patients and to hospitals with neurogastroenterology expertise, and coverage limitations from CMS and commercial payers that restrict payment to established centres with formal gastroparesis programmes.

For related market intelligence, see the Gastroenterology Drug Market.